InspireMD (NYSE:NSPR) Insider Sells $12,624.72 in Stock

Posted by George Bondi on May 24th, 2026

InspireMD, Inc. (NYSE:NSPR – Get Free Report) insider Shane Thomas Gleason sold 5,132 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.46, for a total transaction of $12,624.72. Following the transaction, the insider directly owned 1,104,601 shares of the company’s stock, valued at $2,717,318.46. This trade represents a 0.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total transaction of $23,005.78.

InspireMD Stock Performance

Shares of NSPR stock opened at $1.00 on Friday. InspireMD, Inc. has a one year low of $0.97 and a one year high of $2.93. The company has a 50 day moving average price of $1.38 and a 200 day moving average price of $1.66. The firm has a market capitalization of $46.84 million, a price-to-earnings ratio of -1.33 and a beta of 0.82.

Analysts Set New Price Targets

NSPR has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Loop Capital set a $5.00 price objective on shares of InspireMD in a research note on Tuesday, February 24th. Maxim Group initiated coverage on shares of InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Finally, Lake Street Capital set a $4.00 price objective on shares of InspireMD in a research note on Monday, May 4th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $4.50.

Get Our Latest Report on NSPR

Key Headlines Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

Positive Sentiment: Wall Street still has a constructive view on InspireMD, with multiple analysts maintaining Buy ratings and a consensus price target well above the current share price. InspireMD (NSPR) Stock Forecast & Price Target
Neutral Sentiment: The latest insider sale by Shane Thomas Gleason involved 3,858 shares and was disclosed as being related to tax withholding obligations from vested equity awards, which often makes the transaction less meaningful as a trading signal. SEC filing
Neutral Sentiment: There were several earlier insider sales by the same executive this month and in prior months, but the reported amounts were relatively small and also tied to equity-award tax obligations. SEC filing
Negative Sentiment: Multiple insider sales can still pressure sentiment because investors may interpret them as limited near-term confidence, especially with NSPR trading near its 52-week low and below key moving averages. SEC filing

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in shares of InspireMD in the first quarter valued at $29,000. XTX Topco Ltd purchased a new position in shares of InspireMD in the fourth quarter valued at $30,000. Virtu Financial LLC purchased a new position in shares of InspireMD in the fourth quarter valued at $31,000. Creative Planning purchased a new position in shares of InspireMD in the second quarter valued at $44,000. Finally, Legato Capital Management LLC purchased a new position in shares of InspireMD in the fourth quarter valued at $48,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

InspireMD Company Profile

(Get Free Report)

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.